Analysts Offer Predictions for Disc Medicine Q2 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Analysts at Lifesci Capital issued their Q2 2025 earnings per share (EPS) estimates for Disc Medicine in a research note issued on Monday, June 16th. Lifesci Capital analyst R. Katkhuda forecasts that the company will earn ($1.05) per share for the quarter. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share. Lifesci Capital also issued estimates for Disc Medicine’s Q3 2025 earnings at ($1.07) EPS.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.03).

A number of other equities research analysts have also weighed in on IRON. Morgan Stanley reissued an “overweight” rating and set a $85.00 price objective on shares of Disc Medicine in a report on Friday, March 7th. Raymond James Financial started coverage on shares of Disc Medicine in a report on Wednesday, June 11th. They set a “strong-buy” rating and a $89.00 price objective on the stock. Cantor Fitzgerald boosted their price objective on shares of Disc Medicine from $99.00 to $132.00 and gave the company an “overweight” rating in a report on Tuesday, March 18th. Wedbush reissued an “outperform” rating and set a $90.00 price objective on shares of Disc Medicine in a report on Monday. Finally, HC Wainwright reissued a “buy” rating and set a $118.00 price objective on shares of Disc Medicine in a report on Tuesday. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $96.70.

Disc Medicine Stock Performance

Shares of IRON stock opened at $50.05 on Tuesday. The business’s fifty day simple moving average is $46.44 and its 200-day simple moving average is $53.08. The company has a market cap of $1.73 billion, a PE ratio of -12.77 and a beta of 0.73. The company has a current ratio of 37.65, a quick ratio of 37.65 and a debt-to-equity ratio of 0.04. Disc Medicine has a 12-month low of $30.82 and a 12-month high of $68.73.

Insider Buying and Selling at Disc Medicine

In other Disc Medicine news, insider William Jacob Savage sold 2,100 shares of the company’s stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $50.17, for a total value of $105,357.00. Following the sale, the insider now directly owns 66,398 shares of the company’s stock, valued at approximately $3,331,187.66. This represents a 3.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mona Ashiya sold 10,011 shares of the company’s stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $54.00, for a total transaction of $540,594.00. Following the completion of the transaction, the director now owns 187,297 shares of the company’s stock, valued at approximately $10,114,038. This trade represents a 5.07% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 27,522 shares of company stock valued at $1,440,351. 4.24% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IRON. RA Capital Management L.P. acquired a new position in shares of Disc Medicine in the first quarter worth about $78,288,000. FMR LLC raised its position in shares of Disc Medicine by 358.7% in the fourth quarter. FMR LLC now owns 1,866,248 shares of the company’s stock worth $118,320,000 after acquiring an additional 1,459,434 shares during the period. Siren L.L.C. acquired a new position in shares of Disc Medicine in the first quarter worth about $53,207,000. Wellington Management Group LLP raised its position in shares of Disc Medicine by 67.9% in the first quarter. Wellington Management Group LLP now owns 2,343,499 shares of the company’s stock worth $116,331,000 after acquiring an additional 948,094 shares during the period. Finally, Janus Henderson Group PLC raised its position in shares of Disc Medicine by 62.4% in the fourth quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company’s stock worth $77,170,000 after acquiring an additional 467,988 shares during the period. Institutional investors and hedge funds own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.